
Over the last 7 days, the Clinical Research and Equipment industry has remained flat, although notably Locus Cell declined by 9.1%. Unfortunately though, the industry is down 4.0% over the past 12 months.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 08 Jun 2026 | NT$32.7b | NT$2.7b | -NT$746,869,000.00 | 21.3x | -43.8x | 12.3x |
| Wed, 06 May 2026 | NT$35.8b | NT$2.5b | -NT$764,028,000.00 | 21.6x | -46.8x | 14.2x |
| Fri, 03 Apr 2026 | NT$31.0b | NT$2.5b | -NT$750,275,000.00 | 20.4x | -41.3x | 12.4x |
| Sun, 01 Mar 2026 | NT$33.0b | NT$2.4b | -NT$692,870,000.00 | 19.9x | -47.7x | 13.6x |
| Tue, 27 Jan 2026 | NT$34.7b | NT$2.4b | -NT$689,929,000.00 | 24.7x | -50.2x | 14.3x |
| Thu, 25 Dec 2025 | NT$34.7b | NT$2.4b | -NT$670,921,000.00 | 24.5x | -51.7x | 14.2x |
| Sat, 22 Nov 2025 | NT$36.5b | NT$2.4b | -NT$670,921,000.00 | 19.1x | -54.4x | 14.9x |
| Mon, 20 Oct 2025 | NT$37.4b | NT$2.5b | -NT$870,437,000.00 | 18.7x | -43x | 15.2x |
| Wed, 17 Sep 2025 | NT$34.8b | NT$2.5b | -NT$819,216,000.00 | 20.1x | -42.4x | 14.2x |
| Fri, 15 Aug 2025 | NT$34.1b | NT$2.5b | -NT$599,930,000.00 | 20.4x | -56.9x | 13.8x |
| Sun, 13 Jul 2025 | NT$33.1b | NT$2.5b | -NT$600,003,000.00 | 22.5x | -55.2x | 13.5x |
| Tue, 10 Jun 2025 | NT$34.2b | NT$2.5b | -NT$600,003,000.00 | 23.2x | -56.9x | 13.9x |
| Thu, 08 May 2025 | NT$30.9b | NT$2.5b | -NT$540,128,000.00 | 23.1x | -57.2x | 12.5x |
| Sat, 05 Apr 2025 | NT$35.4b | NT$2.5b | -NT$536,440,000.00 | 25.7x | -66.1x | 14.4x |
| Mon, 03 Mar 2025 | NT$36.8b | NT$2.6b | -NT$854,432,000.00 | 24.3x | -43.1x | 14.3x |
| Wed, 29 Jan 2025 | NT$36.8b | NT$2.6b | -NT$854,432,000.00 | 23.5x | -43.1x | 14.4x |
| Fri, 27 Dec 2024 | NT$33.8b | NT$2.6b | -NT$854,432,000.00 | 22.7x | -39.6x | 13.2x |
| Sun, 24 Nov 2024 | NT$40.6b | NT$2.6b | -NT$854,432,000.00 | 24x | -47.5x | 15.8x |
| Tue, 22 Oct 2024 | NT$40.8b | NT$2.3b | -NT$836,610,000.00 | 22.5x | -48.7x | 17.9x |
| Thu, 19 Sep 2024 | NT$42.3b | NT$2.3b | -NT$836,610,000.00 | 21.8x | -50.5x | 18.6x |
| Sat, 17 Aug 2024 | NT$40.8b | NT$2.1b | -NT$791,513,000.00 | 28x | -51.6x | 19.2x |
| Mon, 15 Jul 2024 | NT$43.9b | NT$2.1b | -NT$797,765,000.00 | 33.9x | -55x | 20.6x |
| Wed, 12 Jun 2024 | NT$40.4b | NT$2.1b | -NT$797,765,000.00 | 33x | -50.6x | 18.9x |
| Fri, 10 May 2024 | NT$40.0b | NT$2.1b | -NT$914,899,000.00 | 32.2x | -43.7x | 18.8x |
| Sun, 07 Apr 2024 | NT$40.0b | NT$2.1b | -NT$903,875,000.00 | 31.6x | -44.3x | 19x |
| Tue, 05 Mar 2024 | NT$43.3b | NT$2.1b | -NT$610,218,000.00 | 33x | -70.9x | 20.8x |
| Thu, 01 Feb 2024 | NT$43.7b | NT$2.1b | -NT$610,218,000.00 | 32.8x | -71.6x | 21.1x |
| Sat, 30 Dec 2023 | NT$47.8b | NT$2.1b | -NT$610,218,000.00 | 33.3x | -78.4x | 23x |
| Mon, 27 Nov 2023 | NT$48.4b | NT$2.1b | -NT$610,218,000.00 | 31.4x | -79.3x | 23.3x |
| Wed, 25 Oct 2023 | NT$49.2b | NT$2.2b | -NT$497,769,000.00 | 31.2x | -98.9x | 22.1x |
| Fri, 22 Sep 2023 | NT$44.7b | NT$2.2b | -NT$497,769,000.00 | 30.7x | -89.8x | 20.1x |
| Sun, 20 Aug 2023 | NT$43.3b | NT$2.2b | -NT$497,769,000.00 | 31.1x | -86.9x | 19.4x |
| Tue, 18 Jul 2023 | NT$48.4b | NT$2.5b | -NT$274,767,000.00 | 42.1x | -176.2x | 19.7x |
| Thu, 15 Jun 2023 | NT$48.6b | NT$2.5b | -NT$274,767,000.00 | 44.2x | -176.9x | 19.8x |
-176.9x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 0.45% | |
| Healthcare | 2.02% | |
| Life Sciences | 0.97% | |
| Clinical Research and Equipment | 0.97% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6986 HeXun Biosciences | NT$66.40 | 6.6% +NT$188.6m | -10.6% | PE27.3x | |
| 6662 BioLASCO Taiwan | NT$29.40 | 2.1% +NT$15.4m | -13.7% | PE17.4x | |
| 6848 RBC Bioscience | NT$19.65 | 0.3% +NT$713.7k | 15.0% | PE11.9x |